New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.62 0.56 +1.22%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Where the cash went Fiscal 2025, year to Dec 31, 2025

Dividends and buybacks of $10.9B were more than free cash flow of $9.1B; $1.7B of new borrowing made up the difference. Cash rose by $244.4M. What is a cash flow statement?

Free cash flow
$9.1B 75.0% of operating cash flow
Returned to shareholders
$10.9B 119.9% of free cash flow
Debt, net
$1.7B borrowed
Change in cash
+$244.4M over the period
Where the cash went, in billions of dollars
Operating cash flow12.2
Capital expenditures−3.0
Free cash flow9.1
Acquisitions, net+11.8
Into investments, net−11.4
Dividends−5.4
Buybacks, net−5.5
Debt raised, net+1.7
Change in cash0.2
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, ten years
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Operating cash flow$8.7B$8.3B$6.6B$8.7B$8.5B$12.4B$11.1B$11.1B$9.8B$12.2B
Capex−$2.1B−$1.6B$220M−$663M−$1.4B−$1.6B−$751M−$2.2B−$1.9B−$3.0B
Free cash flow$6.6B$6.7B$6.8B$8.0B$7.1B$10.9B$10.3B$8.9B$8.0B$9.1B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
5,587.98 5,947.22 5,844.42 8,819.69 7,362.43 14,066.28 3,142.72 5,085.39 9,532.95 5,210.98
Operating Cash Flow
12,162.55 9,826.55 11,102.23 11,090.19 12,448.58 8,508.99 8,673.28 6,551.01 8,340.48 8,673.53
Investing cash flow
(2,768.54) (4,768.81) (6,710.26) (2,186.22) (8,634.26) 4,098.57 (1,357.44) (15,194.75) (3,273.35) (2,778.67)
Financing cash flow
(9,285.40) (6,236.14) (8,714.68) (6,133.00) (8,347.95) (7,407.81) (4,696.16) 4,646.05 (8,931.63) (4,538.17)
Ending Cash
8,663.13 8,051.91 9,426.83 13,418.65 11,946.94 15,895.10 10,558.24 8,178.43 11,659.04 11,368.10
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026